PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report) shares were down 0.5% during trading on Friday . The stock traded as low as $0.6874 and last traded at $0.6965. 53,074 shares changed hands during trading, an increase of 501% from the average daily volume of 8,831 shares. The stock had previously closed at $0.70.
PharmaCyte Biotech Stock Down 0.5%
The stock has a 50 day moving average price of $0.75 and a two-hundred day moving average price of $0.75.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical‐stage biotechnology company focused on the development and commercialization of targeted cellular therapies for cancer and diabetes. The company’s core technology, Cell-in-a-Box, encapsulates live, genetically modified cells within a proprietary cellulose‐based polymer matrix. This platform is designed to deliver therapeutic agents directly at tumor sites or within the pancreas, with the goal of maximizing efficacy while minimizing systemic side effects.
In its lead oncology program, PharmaCyte is conducting clinical trials for advanced pancreatic cancer, combining Cell-in-a-Box–encased cells with the prodrug ifosfamide.
Further Reading
- Five stocks we like better than PharmaCyte Biotech
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
